GLPwatch

Soliqua vs Xultophy

Drug comparison

Last updated 2026-05-28 15:46 UTC

Soliqua contains the active ingredient lixisenatide and is made by Sanofi, while Xultophy contains liraglutide and is made by Novo Nordisk. Both are injected under the skin to treat type 2 diabetes, but they use different active ingredients and are produced by different companies.

AI summary of the sources below.

Soliqua Xultophy
Active ingredientlixisenatideliraglutide
Manufacturersanofinovo-nordisk
Routesubcutaneous injectionsubcutaneous injection
FDA-approved fortype 2 diabetestype 2 diabetes
Label updated2026-03-182025-10-14

Compare full details on the Soliqua and Xultophy pages.